Archer Materials
Corporate

Archer Materials Limited (ACN: 123 993 233)
Lot Fourteen, Frome Road, Adelaide SA 5000
www.archerx.com.au

ASX Announcement (ASX: **AXE**) 29 January 2026

Investor Webinar - Presentation

Archer Materials Limited ("Archer", the "Company", "ASX: AXE") is pleased to enclose a copy of the Presentation to be delivered by Archer's Chief Executive Officer, Simon Ruffell, at 11:00am AEDT today, followed by a Q&A session.

To attend, please register at:

https://us02web.zoom.us/webinar/register/WN_kxDWbeV_SFO07dC1iOqICg

The Executive Chair of Archer authorised this announcement to be given to ASX.

Investor enquiries

Luke Maffei
+61 403 193 579
luke.maffei@automicgroup.com.au

Media enquiries

Dylan Mark
+61 475 783 675
dylan.mark@automicgroup.com.au

About Archer

Archer is a quantum technology company that operates within the semiconductor industry. The Company is developing advanced semiconductor devices, including chips relevant to quantum computing, sensing, and medical diagnostics. Archer utilises its global partnerships to develop these technologies for potential deployment and use across multiple industries. www.archerx.com.au

Q2 FY26 update

Simon Ruffell, Chief Executive Officer

29 January 2026

Archer at a glance

Archer Materials (ASX: AXE) is the only ASX-listed quantum technology company. We are developing IP for use in quantum computing, sensing and medical diagnostics.



- Technology roadmap of quantum IP in medical, sensing, and computing.
- Headquarters in Australia
- Over 40 patents filed globally.
- Development partnerships with world-class R&D institutions and industry leaders.

Significant advantages of Archer's quantum chip

Designed for scalability

Built with materials and processes that can scale using today's semiconductor fabrication methods and integrated with today's chips.

Improved control

Archer's chip will have improved control capabilities and stability, enabling the calculation of more complex calculations.

Versatile foundation

Unique carbon-based materials provide a foundation for advanced technologies in sensing and low-power electronics in additions to computing.

Commercial focus

Development roadmap aimed at licensing and industry partnerships rather than building full quantum machines in-house.

Quantum sensing for next-gen deep tech applications

Developing quantum sensors with exceptional precision for advanced markets in AI hardware, data centres, IoT, autonomous vehicles, medicine, and more.

Quantum sensing underpins emerging markets where high sensitivity, energy efficiency, miniaturisation are critical.



Collaborating with industry and R&D partners to develop prototype quantum sensing devices, while identifying initial industrial and data-driven applications ahead of prototype development in 2026.

Built on the same carbon-based and quantum expertise that underpins and extends Archer's core IP.

BIOCHIP

A Sensing Platform

Archer is developing a world-first biosensor to measure blood potassium levels from a simple finger-prick sample, allowing for regular point-of-care and at-home monitoring of chronic kidney disease patients.

- Archer's Biochip is the first advancement in portable diagnostics in over 40 years, and the world's first portable biosensor for finger-prick blood potassium testing.
- 850 million people globally suffer from chronic kidney disease; lab tests infrequent → risk of hyperkalemia
- US $3 billion TAM within US $80 billion renal care market.
- Standard semiconductor manufacturing processes integration completed; partnership with IMEC; prototype target 2026.
- Building feasibility data on the sensing platform for other applications in industry, human health, and ag-tech.

Beyond this beachhead application, the platform will address a range of other markets.

Concept image.

Built to prevent life-threatening cardiac events.

Potassium Sensor

Chip - Highly sensitive, fast response, low power

Haemolysis Sensor

Eliminates false positives from blood cell rupture

Accessible

Simple point-of-care and at-home testing, even in rural or remote areas

Q2 FY26 Highlights

Delivered technical milestones, positioning Archer for key product demonstrations in 2026

Quantum computing & sensing

- Improved quantum state readout for carbon qubit materials, demonstrated through electrical detection using EDMR and SET circuitry.
- This helps de-risk the technology and makes it more foundry-ready for manufacture.
- Signed a collaboration agreements with Emergence Quantum and CSIRO to advance its range of quantum and electronic devices, and to develop QML models for financial fraud detection, respectively.

Biochip

- Demonstrated that the graphene-based device can be built onto silicon with faster readout times, with IMEC
- Met blood potassium testing accuracy requirements for clinical standards, bolstering its path to regulatory approval.
- Silicon is more widely used in the industry and therefore helps bring the Biochip closer to manufacture and commercialisation.

Corporate

- Receipt of an R&D tax rebate from the Australian government of $2.1 million
- Cash balance of $10.3 million with no debt as of 31 December 2025
- Appointed Mr Andrew Just as Non-Executive Director. Mr Just is an experienced director and health industry executive with 30 years of global experience in delivering growth and scaling companies and technologies

Commercial roadmap

Archer's three programs follow parallel paths from proof-of-concept to product demonstration and commercial partnerships.

Technology	2025	2026	2027	2028+
Quantum computing	Achieved key qubit milestones, including improved control and readout. Commenced QML project with CSIRO.	Qubit demonstration targeted (proof of function). QML prototype built, including data sets and software.	Scale-up of quantum devices and software; engage in industry collaboration and IP licensing discussions.	Licensing arrangements of developed utility-scale hardware and software.
Biochip	IMEC partnership initiated; lab prototype work underway.	Prototype targeted in 2026; begin regulatory and clinical preparation.	Clinical trials in 2027; establish commercial partnerships in diagnostics sector.	Go-to market.
Quantum sensing	Foundry collaboration initiated; application identification phase in progress.	Prototype development in 2026; define go-to-market strategy.	Early customer engagement and validation for industrial and AI sensing applications.	Go-to market.

2026 Key Milestones

Calendar years to 2027



- Lab demonstrator/alpha prototype of blood potassium early 2026.
- Blood potassium prototype sensor in 2026 for use in trials
- End of 2026 begin clinical trials for blood potassium sensor
- Targeting quantum sensing application and market validation early 2026 (TMR, carbon)
- Work to begin on development of next generation biosensor from R&D – early 2026
- Carbon-based quantum qubit demonstration (computing) & QML demonstration

Thank you

ASX Code: AXE

The Executive Chair of Archer Materials authorised this announcement to be given to the ASX.

Sydney

Level 2, 477 Pitt St
Sydney NSW 2000

Adelaide

Lot Fourteen, Frome Rd
Adelaide SA 5000

Subscribe to our newsletter